vs
Insulet Corporation（PODD）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
Insulet Corporation的季度营收约是RBC Bearings INC的1.7倍（$783.7M vs $461.6M），RBC Bearings INC净利率更高（14.6% vs 13.0%，领先1.6%），Insulet Corporation同比增速更快（31.2% vs 17.0%），RBC Bearings INC自由现金流更多（$99.1M vs $48.2M），过去两年Insulet Corporation的营收复合增速更高（33.2% vs 5.6%）
Insulet Corporation是深耕糖尿病治疗领域的医疗器械企业，核心产品为胰岛素泵，通过持续皮下输注胰岛素的疗法为患者给药。其产品通常由泵主体、一次性胰岛素储药仓，以及包含皮下植入套管和连接管路的一次性输注套件构成，满足不同患者的治疗需求。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
PODD vs RBC — 直观对比
营收规模更大
PODD
是对方的1.7倍
$461.6M
营收增速更快
PODD
高出14.1%
17.0%
净利率更高
RBC
高出1.6%
13.0%
自由现金流更多
RBC
多$50.9M
$48.2M
两年增速更快
PODD
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $783.7M | $461.6M |
| 净利润 | $101.6M | $67.4M |
| 毛利率 | 72.6% | 44.3% |
| 营业利润率 | 18.7% | 22.3% |
| 净利率 | 13.0% | 14.6% |
| 营收同比 | 31.2% | 17.0% |
| 净利润同比 | 0.9% | 16.4% |
| 每股收益（稀释后） | $1.42 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PODDRBC
| Q4 25 | $783.7M | $461.6M | ||
| Q3 25 | $706.3M | $455.3M | ||
| Q2 25 | $649.1M | $436.0M | ||
| Q1 25 | $569.0M | $437.7M | ||
| Q4 24 | $597.5M | $394.4M | ||
| Q3 24 | $543.9M | $397.9M | ||
| Q2 24 | $488.5M | $406.3M | ||
| Q1 24 | $441.7M | $413.7M |
净利润PODDRBC
| Q4 25 | $101.6M | $67.4M | ||
| Q3 25 | $87.6M | $60.0M | ||
| Q2 25 | $22.5M | $68.5M | ||
| Q1 25 | $35.4M | $72.7M | ||
| Q4 24 | $100.7M | $57.9M | ||
| Q3 24 | $77.5M | $54.2M | ||
| Q2 24 | $188.6M | $61.4M | ||
| Q1 24 | $51.5M | — |
毛利率PODDRBC
| Q4 25 | 72.6% | 44.3% | ||
| Q3 25 | 72.2% | 44.1% | ||
| Q2 25 | 69.7% | 44.8% | ||
| Q1 25 | 71.9% | 44.2% | ||
| Q4 24 | 72.1% | 44.3% | ||
| Q3 24 | 69.3% | 43.7% | ||
| Q2 24 | 67.7% | 45.3% | ||
| Q1 24 | 69.5% | 43.1% |
营业利润率PODDRBC
| Q4 25 | 18.7% | 22.3% | ||
| Q3 25 | 16.7% | 21.5% | ||
| Q2 25 | 18.7% | 23.2% | ||
| Q1 25 | 15.6% | 23.0% | ||
| Q4 24 | 18.3% | 21.7% | ||
| Q3 24 | 16.2% | 21.6% | ||
| Q2 24 | 11.2% | 24.0% | ||
| Q1 24 | 12.9% | 22.8% |
净利率PODDRBC
| Q4 25 | 13.0% | 14.6% | ||
| Q3 25 | 12.4% | 13.2% | ||
| Q2 25 | 3.5% | 15.7% | ||
| Q1 25 | 6.2% | 16.6% | ||
| Q4 24 | 16.9% | 14.7% | ||
| Q3 24 | 14.2% | 13.6% | ||
| Q2 24 | 38.6% | 15.1% | ||
| Q1 24 | 11.7% | — |
每股收益（稀释后）PODDRBC
| Q4 25 | $1.42 | $2.13 | ||
| Q3 25 | $1.24 | $1.90 | ||
| Q2 25 | $0.32 | $2.17 | ||
| Q1 25 | $0.50 | $2.33 | ||
| Q4 24 | $1.38 | $1.82 | ||
| Q3 24 | $1.08 | $1.65 | ||
| Q2 24 | $2.59 | $1.90 | ||
| Q1 24 | $0.73 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $107.6M |
| 总债务越低越好 | $930.8M | $990.2M |
| 股东权益账面价值 | $1.5B | $3.3B |
| 总资产 | $3.2B | $5.1B |
| 负债/权益比越低杠杆越低 | 0.61× | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资PODDRBC
| Q4 25 | — | $107.6M | ||
| Q3 25 | — | $91.2M | ||
| Q2 25 | — | $132.9M | ||
| Q1 25 | — | $36.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $76.8M | ||
| Q1 24 | — | $63.5M |
总债务PODDRBC
| Q4 25 | $930.8M | $990.2M | ||
| Q3 25 | $934.9M | $1.1B | ||
| Q2 25 | $939.0M | $915.6M | ||
| Q1 25 | $1.6B | $920.1M | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | $1.2B |
股东权益PODDRBC
| Q4 25 | $1.5B | $3.3B | ||
| Q3 25 | $1.4B | $3.2B | ||
| Q2 25 | $1.5B | $3.1B | ||
| Q1 25 | $1.3B | $3.0B | ||
| Q4 24 | $1.2B | $2.9B | ||
| Q3 24 | $1.1B | $2.9B | ||
| Q2 24 | $998.4M | $2.8B | ||
| Q1 24 | $790.7M | $2.8B |
总资产PODDRBC
| Q4 25 | $3.2B | $5.1B | ||
| Q3 25 | $3.0B | $5.1B | ||
| Q2 25 | $3.5B | $4.8B | ||
| Q1 25 | $3.5B | $4.7B | ||
| Q4 24 | $3.1B | $4.7B | ||
| Q3 24 | $3.0B | $4.7B | ||
| Q2 24 | $2.9B | $4.7B | ||
| Q1 24 | $2.6B | $4.7B |
负债/权益比PODDRBC
| Q4 25 | 0.61× | 0.30× | ||
| Q3 25 | 0.68× | 0.34× | ||
| Q2 25 | 0.64× | 0.29× | ||
| Q1 25 | 1.21× | 0.30× | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 1.72× | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.3M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $48.2M | $99.1M |
| 自由现金流率自由现金流/营收 | 6.2% | 21.5% |
| 资本支出强度资本支出/营收 | 17.2% | 5.0% |
| 现金转化率经营现金流/净利润 | 1.80× | 1.81× |
| 过去12个月自由现金流最近4个季度 | $377.7M | — |
8季度趋势，按日历期对齐
经营现金流PODDRBC
| Q4 25 | $183.3M | $122.1M | ||
| Q3 25 | $125.7M | $88.4M | ||
| Q2 25 | $196.5M | $120.0M | ||
| Q1 25 | $63.8M | — | ||
| Q4 24 | $147.7M | $84.0M | ||
| Q3 24 | $98.5M | — | ||
| Q2 24 | $96.5M | $97.4M | ||
| Q1 24 | $87.6M | — |
自由现金流PODDRBC
| Q4 25 | $48.2M | $99.1M | ||
| Q3 25 | $100.1M | $71.7M | ||
| Q2 25 | $177.9M | $104.3M | ||
| Q1 25 | $51.5M | — | ||
| Q4 24 | $94.1M | $73.6M | ||
| Q3 24 | $71.8M | — | ||
| Q2 24 | $74.0M | $88.4M | ||
| Q1 24 | $65.5M | — |
自由现金流率PODDRBC
| Q4 25 | 6.2% | 21.5% | ||
| Q3 25 | 14.2% | 15.7% | ||
| Q2 25 | 27.4% | 23.9% | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 15.7% | 18.7% | ||
| Q3 24 | 13.2% | — | ||
| Q2 24 | 15.1% | 21.8% | ||
| Q1 24 | 14.8% | — |
资本支出强度PODDRBC
| Q4 25 | 17.2% | 5.0% | ||
| Q3 25 | 3.6% | 3.7% | ||
| Q2 25 | 2.9% | 3.6% | ||
| Q1 25 | 2.2% | 3.2% | ||
| Q4 24 | 9.0% | 2.6% | ||
| Q3 24 | 4.9% | 4.1% | ||
| Q2 24 | 4.6% | 2.2% | ||
| Q1 24 | 5.0% | — |
现金转化率PODDRBC
| Q4 25 | 1.80× | 1.81× | ||
| Q3 25 | 1.43× | 1.47× | ||
| Q2 25 | 8.73× | 1.75× | ||
| Q1 25 | 1.80× | — | ||
| Q4 24 | 1.47× | 1.45× | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | 0.51× | 1.59× | ||
| Q1 24 | 1.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
